A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy

Cancer

Volumn 115, Issue 19, 2009, Pages 4547-4553

  Tucci, Alessandra ^a,b   Ferrari, Samantha ^a   Bottelli, Chiara ^a   Borlenghi, Erika ^a   Drera, Monica ^a   Rossi, Giuseppe ^a  

^a Spedali Civili ^*  (Italy)

^b UO Ematologia   (Italy)

Author keywords

Anthracycline; Comprehensive geriatric assessment; Diffuse large cell lymphoma; Elderly patients

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT; DEATH; FEMALE; GERIATRIC ASSESSMENT; HUMAN; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DECISION MAKING; DOXORUBICIN; FEMALE; GERIATRIC ASSESSMENT; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PALLIATIVE CARE; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 70349275955     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24490     Document Type: Article

References (16)

1. Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am. 2000;14:1-16.
2. Kouroukis C, Browman G, Esmail R, et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non Hodgkin lymphoma: a systematic review. Ann Intern Med. 2002;136:144-152. (Pubitemid 34073939)
3. Peters FPJ, Lalisang RI, Fickers MMF, et al. Treatment of elderly patients with intermediate and high grade non Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol. 2001;80:155-159.
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adult. J Clin Oncol. 2005;23:4117-4126. (Pubitemid 46211317)
5. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007;25:1916-1923.
6. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000;35:147-154. (Pubitemid 30674141)
7. Extermann M, Hurria A. Comprehensive Geriatric Assessment for older patients with cancer. J Clin Oncol. 2007;25:1824-1831. (Pubitemid 46860271)
8. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL-A standardized measure of biological and psychosocial function. JAMA. 1963;185:914-919.
9. Miller MD, Towers A. A Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRSG). Pittsburg, PA: University of Pittsburg; 1991.
10. The International Non Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
11. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
13. Karnofsky DA: Clinical evaluation of anticancer drugs: cancer chemotherapy. Gann Monogr. 1967;2:223-321.
14. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOPlike chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
15. Intragumtornchai T, Bunworasate U, Nakorn TN, et al. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:1306-1314. (Pubitemid 44269638)
16. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in highrisk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262. (Pubitemid 46606401)